Moderna reports Q4 earnings beat, upbeat 2026 outlook
The report comes after Moderna said the FDA is refusing to consider an application for its mRNA flu vaccine.
Moderna reported Q4 earnings results on Friday that beat Wall Street estimates and also gave cheery full-year sales guidance for 2026, which comes as the company faces major regulatory headwinds.
For the last three months of 2025, Moderna reported:
Loss per share of $2.11, less than the $2.54 loss per share analysts polled by FactSet had been expecting.
Revenue of $678 million, more than the $635 million the Street was expecting. The company had already disclosed preliminary full-year 2025 sales in January, which was in line with the $1.9 billion the company reported on Friday.
For the full-year 2026, the company expects:
Revenue to grow 10%. Currently, analysts are penciling $2 billion in 2026 sales, which is about a 5% increase.
The company's 2025 sales came in higher than analysts initially expected, driven by lower-than-anticipated declines in vaccination rates despite attacks from the Trump administration.
Moderna was tapped by the US government to quickly develop a vaccine for COVID-19 in 2020, a product that remains its single source of revenue. Investors have been eager to see the company roll out new products in its pipeline, but a hostile regulatory environment has complicated those plans.
Moderna said earlier this week that the Food and Drug Administration is refusing to consider an application for its mRNA flu vaccine. The company said in that announcement that it would not have an impact on its 2026 guidance.
The company said the filing was accepted by the European Union, Canada and Australia. Company guidance predicts 2026 sales will be 50% international.
